In this July 9, 2015, file photo, a man walks outside the headquarters of Gilead Sciences in Foster City, Calif.
Eric Risberg | AP
Gilead Sciences said Wednesday it is aware of “positive data” from one of its studies looking at antiviral drug remdesivir as a potential treatment for the coronavirus.
Shares of Gilead were halted in premarket trading.
The drugmaker was expected this week to release clinical trial results involving patients with severe cases of Covid-19. The severe study is “single-arm,” meaning it will not evaluate the drug against a control group of patients who didn’t receive the drug.
There are no proven treatments for Covid-19, which has infected more than 3 million people worldwide and killed at least 217,569 as of Wednesday morning, according to data compiled by Johns Hopkins University. U.S. health officials say producing a vaccine to prevent the disease will take at least 12 to 18 months, making finding an effective drug treatment soon even more crucial.
This is breaking news. Please check back for updates.